Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.

Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.

Mult Scler Relat Disord. 2019 Apr;29:168-174. doi: 10.1016/j.msard.2019.01.038. Epub 2019 Jan 24.

2.

Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.

Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L.

Clin Ther. 2019 Feb;41(2):249-260.e18. doi: 10.1016/j.clinthera.2018.12.015.

3.

Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart®.

Rieckmann P, Schwab M, Pöhlau D, Penner IK, Wagner T, Schel E, Bayas A.

Adv Ther. 2019 Jan;36(1):175-186. doi: 10.1007/s12325-018-0839-1. Epub 2018 Nov 28.

PMID:
30488338
4.

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier.

Yeandle D, Rieckmann P, Giovannoni G, Alexandri N, Langdon D.

Neurol Ther. 2018 Dec;7(2):179-187. doi: 10.1007/s40120-018-0118-8. Epub 2018 Nov 9.

5.

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.

Mult Scler. 2019 May;25(6):819-827. doi: 10.1177/1352458518771875. Epub 2018 May 2.

6.

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA.

J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.

PMID:
29696498
7.

The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset.

Amram O, Schuurman N, Randall E, Zhu F, Saeedi J, Rieckmann P, Yee I, Tremlett H.

Mult Scler Relat Disord. 2018 Apr;21:30-34. doi: 10.1016/j.msard.2018.02.005. Epub 2018 Feb 6.

PMID:
29455071
8.

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Members of the MS in the 21st Century Steering Group:, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G, Langdon D, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P, Aston K, Bauer B, Demory C, Giambastiani MP, Hlavacova J, Nouvet-Gire J, Pepper G, Pontaga M, Rogan E, Rogalski C, van Galen P, Ben-Amor AF.

Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.

9.

Lethal outcome after pelvic salvage radiotherapy in a patient with prostate cancer due to increased radiosensitivity : Case report and literature review.

Fahrig A, Koch T, Lenhart M, Rieckmann P, Fietkau R, Distel L, Schuster B.

Strahlenther Onkol. 2018 Jan;194(1):60-66. doi: 10.1007/s00066-017-1207-9. Epub 2017 Sep 8. Review.

PMID:
28887683
10.

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.

Mult Scler. 2018 Oct;24(12):1594-1604. doi: 10.1177/1352458517727603. Epub 2017 Sep 5.

PMID:
28870107
11.

SPARC expression by cerebral microvascular endothelial cells in vitro and its influence on blood-brain barrier properties.

Alkabie S, Basivireddy J, Zhou L, Roskams J, Rieckmann P, Quandt JA.

J Neuroinflammation. 2016 Aug 31;13(1):225. doi: 10.1186/s12974-016-0657-9.

12.

Electrophysiological assessment of nociception in patients with Parkinson's disease: A multi-methods approach.

Priebe JA, Kunz M, Morcinek C, Rieckmann P, Lautenbacher S.

J Neurol Sci. 2016 Sep 15;368:59-69. doi: 10.1016/j.jns.2016.06.058. Epub 2016 Jun 28.

PMID:
27538603
13.

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.

Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R.

Mult Scler. 2017 May;23(6):818-829. doi: 10.1177/1352458516664033. Epub 2016 Aug 8.

PMID:
27503905
14.

Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.

Metz I, Rieckmann P, Kallmann BA, Brück W.

Acta Neuropathol Commun. 2016 Aug 8;4(1):81. doi: 10.1186/s40478-016-0352-1. No abstract available.

15.

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.

Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K.

JAMA Neurol. 2016 Sep 1;73(9):1089-98. doi: 10.1001/jamaneurol.2016.1451.

PMID:
27380540
16.

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C.

G3 (Bethesda). 2016 Jul 7;6(7):2073-9. doi: 10.1534/g3.116.030841.

17.

Does Parkinson's disease lead to alterations in the facial expression of pain?

Priebe JA, Kunz M, Morcinek C, Rieckmann P, Lautenbacher S.

J Neurol Sci. 2015 Dec 15;359(1-2):226-35. doi: 10.1016/j.jns.2015.10.056. Epub 2015 Oct 31.

PMID:
26671119
18.

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS.

Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad DA, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, Hagemann N, Hermann DM, Cournu-Rebeix I, Zipp F, Kümpfel T, Buttmann M, Zettl UK, Fontaine B, Bertram L, Gold R, Chan A.

J Neuroinflammation. 2015 Dec 16;12:234. doi: 10.1186/s12974-015-0429-y.

19.

["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].

Linker R, Kallmann BA, Kleinschnitz C, Rieckmann P, Mäurer M, Schwab S.

Nervenarzt. 2015 Dec;86(12):1528-37. doi: 10.1007/s00115-015-4439-x. Review. German.

PMID:
26556094
20.

Genome-wide significant association with seven novel multiple sclerosis risk loci.

Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Astobiza I, Blaschke P, Boyko AN, Buttmann M, Chan A, Dörner T, Epplen JT, Favorova OO, Fedetz M, Fernández O, García-Martínez A, Gerdes LA, Graetz C, Hartung HP, Hoffjan S, Izquierdo G, Korobko DS, Kroner A, Kubisch C, Kümpfel T, Leyva L, Lohse P, Malkova NA, Montalban X, Popova EV, Rieckmann P, Rozhdestvenskii AS, Schmied C, Smagina IV, Tsareva EY, Winkelmann A, Zettl UK, Binder H, Cournu-Rebeix I, Hintzen R, Zimprich A, Comabella M, Fontaine B, Urcelay E, Vandenbroeck K, Filipenko M, Matesanz F, Zipp F, Bertram L.

J Med Genet. 2015 Dec;52(12):848-55. doi: 10.1136/jmedgenet-2015-103442. Epub 2015 Oct 16.

PMID:
26475045
21.

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P.

Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2. Review.

22.

Functional clinical outcomes in multiple sclerosis: Current status and future prospects.

Karabudak R, Dahdaleh M, Aljumah M, Alroughani R, Alsharoqi IA, AlTahan AM, Bohlega SA, Daif A, Deleu D, Amous A, Inshasi JS, Rieckmann P, Sahraian MA, Yamout BI.

Mult Scler Relat Disord. 2015 May;4(3):192-201. doi: 10.1016/j.msard.2015.03.004. Epub 2015 Mar 23. Review.

PMID:
26008936
23.

ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.

Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J; ATON Trial Group.

J Neurol Sci. 2015 Apr 15;351(1-2):174-178. doi: 10.1016/j.jns.2015.02.019. Epub 2015 Feb 17.

PMID:
25758472
24.

MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene.

Nischwitz S, Wolf C, Andlauer TF, Czamara D, Zettl UK, Rieckmann P, Buck D, Ising M, Bettecken T, Mueller-Myhsok B, Weber F.

J Neuroimmunol. 2015 Feb 15;279:46-9. doi: 10.1016/j.jneuroim.2015.01.008. Epub 2015 Jan 23.

PMID:
25670000
25.

Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.

Lill CM, Schilling M, Ansaloni S, Schröder J, Jaedicke M, Luessi F, Schjeide BM, Mashychev A, Graetz C, Akkad DA, Gerdes LA, Kroner A, Blaschke P, Hoffjan S, Winkelmann A, Dörner T, Rieckmann P, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Zipp F, Bertram L.

Neurogenetics. 2014 May;15(2):129-34. doi: 10.1007/s10048-014-0396-y. Epub 2014 Mar 18.

PMID:
24638856
26.

Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.

Aljumah M, Alroughani R, Alsharoqi I, Bohlega SA, Dahdaleh M, Deleu D, Esmat K, Khalifa A, Sahraian MA, Szólics M, Altahan A, Yamout BI, Rieckmann P, Daif A.

Mult Scler Int. 2013;2013:952321. doi: 10.1155/2013/952321. Epub 2013 Dec 17.

27.

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

Chuang WY, Ströbel P, Bohlender-Willke AL, Rieckmann P, Nix W, Schalke B, Gold R, Opitz A, Klinker E, Inoue M, Müller-Hermelink HK, Saruhan-Direskeneli G, Bugert P, Willcox N, Marx A.

J Autoimmun. 2014 Aug;52:122-9. doi: 10.1016/j.jaut.2013.12.006. Epub 2013 Dec 24.

PMID:
24373506
28.

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.

Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.

Lancet Neurol. 2013 Aug;12(8):756-67. doi: 10.1016/S1474-4422(13)70102-9. Epub 2013 Jun 11. Erratum in: Lancet Neurol. 2013 Sep;12(9):846.

PMID:
23764350
29.

MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium, Lill CM, Schjeide BM, Graetz C, Ban M, Alcina A, Ortiz MA, Pérez J, Damotte V, Booth D, Lopez de Lapuente A, Broer L, Schilling M, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Blaschke P, Buttmann M, Chan A, Compston A, Cournu-Rebeix I, Dörner T, Epplen JT, Fernández Ó, Gerdes LA, Guillot-Noël L, Hartung HP, Hoffjan S, Izquierdo G, Kemppinen A, Kroner A, Kubisch C, Kümpfel T, Li SC, Lindenberger U, Lohse P, Lubetzki C, Luessi F, Malhotra S, Mescheriakova J, Montalban X, Papeix C, Paredes LF, Rieckmann P, Steinhagen-Thiessen E, Winkelmann A, Zettl UK, Hintzen R, Vandenbroeck K, Stewart G, Fontaine B, Comabella M, Urcelay E, Matesanz F, Sawcer S, Bertram L, Zipp F.

Brain. 2013 Jun;136(Pt 6):1778-82. doi: 10.1093/brain/awt101.

30.

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.

Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; GALA Study Group.

Ann Neurol. 2013 Jun;73(6):705-13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.

PMID:
23686821
31.

Re: Errors in the editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670-1672].

Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Vander-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP.

Mult Scler. 2013 May;19(6):831-2. doi: 10.1177/1352458513485150. No abstract available.

PMID:
23658240
32.

Multiple sclerosis in the Arabian Gulf countries: a consensus statement.

Bohlega S, Inshasi J, Al Tahan AR, Madani AB, Qahtani H, Rieckmann P.

J Neurol. 2013 Dec;260(12):2959-63. doi: 10.1007/s00415-013-6876-4. Epub 2013 Mar 17. Review.

33.

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.

Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, Blaschke P, Gerdes LA, Kroner A, Luessi F, Cournu-Rebeix I, Hoffjan S, Winkelmann A, Touze E, Pico F, Corcia P, Otaegui D, Antigüedad A, Alcina A, Comabella M, Montalban X, Olascoaga J, Matesanz F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Rieckmann P, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Fontaine B, Zipp F, Vandenbroeck K, Bertram L.

J Med Genet. 2013 Mar;50(3):140-3. doi: 10.1136/jmedgenet-2012-101411. Epub 2013 Jan 12. No abstract available.

PMID:
23315543
34.

A proposed methodology to estimate the cumulative life-time UVB exposure using geographic information systems: An application to multiple sclerosis.

Schuurman N, Amram O, Saeedi J, Rieckmann P, Yee I, Tremlett H.

Mult Scler Relat Disord. 2013 Jan;2(1):29-35. doi: 10.1016/j.msard.2012.07.003. Epub 2012 Aug 19.

PMID:
25877452
35.

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ.

J Neurol. 2013 Apr;260(4):1136-46. doi: 10.1007/s00415-012-6775-0. Epub 2012 Dec 21.

PMID:
23263473
36.

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.

Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Preziosa P, Ravnborg M, Rieckmann P, Rocca MA, Wynn D, Young C, Filippi M.

Mult Scler. 2013 Jul;19(8):1074-83. doi: 10.1177/1352458512469695. Epub 2012 Dec 12.

PMID:
23234810
37.

[Central pain processing and Parkinson's disease. Epidemiology, physiology, and experimental results issuing pain processing].

Priebe JA, Rieckmann P, Lautenbacher S.

Schmerz. 2012 Dec;26(6):647-54. doi: 10.1007/s00482-012-1222-9. Review. German.

PMID:
23052966
38.

Excitability decreasing central motor plasticity is retained in multiple sclerosis patients.

Zeller D, Dang SY, Weise D, Rieckmann P, Toyka KV, Classen J.

BMC Neurol. 2012 Sep 13;12:92. doi: 10.1186/1471-2377-12-92.

39.

Future MS care: a consensus statement of the MS in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdová E, Hommes O, Lelorier J, Morrow SA, Oreja-Guevara C, Rijke N, Schippling S.

J Neurol. 2013 Feb;260(2):462-9. doi: 10.1007/s00415-012-6656-6. Epub 2012 Aug 31.

40.

The Changes of P-glycoprotein Activity by Interferon-γ and Tumor Necrosis Factor-α in Primary and Immortalized Human Brain Microvascular Endothelial Cells.

Lee NY, Rieckmann P, Kang YS.

Biomol Ther (Seoul). 2012 May;20(3):293-8. doi: 10.4062/biomolther.2012.20.3.293.

41.

Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.

Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP.

Mult Scler. 2012 Dec;18(12):1721-36. doi: 10.1177/1352458512441381. Epub 2012 Mar 28.

42.

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

Grimaldi L, Barkhof F, Beelke M, Burton J, Holmoy T, Hupperts R, Killestein J, Rieckmann P, Schluep M, Smolders J; SOLAR Study Group.

Neurology. 2012 Mar 13;78(11):841. doi: 10.1212/01.wnl.0000413180.13413.ce. No abstract available.

PMID:
22411961
43.

Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada.

Saeedi J, Rieckmann P, Yee I, Tremlett H; UBC MS clinic neurologists.

Mult Scler. 2012 Sep;18(9):1239-43. doi: 10.1177/1352458512436595. Epub 2012 Mar 1.

PMID:
22383230
44.

Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis.

Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R.

Ther Adv Neurol Disord. 2012 Jan;5(1):3-12. doi: 10.1177/1756285611428503.

45.

Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.

Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sørensen P, Vermersch P, Hamlett A, Kurukulasuriya N; CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.

Mult Scler Relat Disord. 2012 Jan;1(1):49-54. doi: 10.1016/j.msard.2011.08.006. Epub 2011 Sep 15.

PMID:
25876451
46.

Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.

Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A; CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.

Clin Drug Investig. 2012 Jan 1;32(1):15-27. doi: 10.2165/11593310-000000000-00000.

PMID:
22017519
47.

Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009).

Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H.

Mult Scler. 2012 Apr;18(4):442-50. doi: 10.1177/1352458511422097. Epub 2011 Sep 27.

PMID:
21952097
48.

Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Bar-Or A, Rieckmann P, Traboulsee A, Yong VW.

CNS Drugs. 2011 Sep 1;25(9):783-99. doi: 10.2165/11587820-000000000-00000. Review.

PMID:
21870889
49.

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.

Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR study group.

J Neurol Sci. 2011 Dec 15;311(1-2):44-9. doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28.

PMID:
21620416
50.

[MusiQol: international questionnaire investigating quality of life in multiple sclerosis: validation results for the German subpopulation in an international comparison].

Flachenecker P, Vogel U, Simeoni MC, Auquier P, Rieckmann P.

Nervenarzt. 2011 Oct;82(10):1281-9. doi: 10.1007/s00115-011-3276-9. German.

PMID:
21472450

Supplemental Content

Loading ...
Support Center